Samiran ghosh (62 Ergebnisse)

Zustand: New.

Zustand: New.

1st ed. 16 x 23 cm. 466 pages. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Sprache: Englisch.

paperback. Zustand: Like New. Most items will be dispatched the same or the next working day. An apparently unread copy in perfect condition. Dust cover is intact with no nicks or tears. Spine has no signs of creasing. Pages are clean and not marred by notes or folds of any kind.

Paperback. Zustand: New. Brand new book, sourced directly from publisher. Dispatch time is 7-8 days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Zustand: New.

Paperback. Zustand: new. Paperback. Marcus is the CEO of a SaaS company that is quietly successful, and quietly dying.The numbers are good. Revenue up fourteen percent year on year. The board is happy. The team is shipping. And Marcus has just realized, sitting on a flight back from an industry conference, that the assumption his company was built on is no longer true. Not in five years. Now.He has sixty days before the next board meeting. Sixty days to decide whether to tell them what he has seen - or to keep performing the comfortable version of the truth until the market makes the decision for him. He has done this once before, at his previous company. He waited too long. He still wakes at three in the morning some nights, holding the regret of seeing something clearly, too late. This time he is not going to wait.OBSOLETE is a business literary novel about the gap between realization and destruction, the narrow window in which every leader either acts on what they have seen, or inherits the wreckage of acting too late.It is a book about Schumpeterian creative destruction told from the inside of a single sixty-day decision: the conversations, the resignations, the architecture of consequence, the cost of acting early, and the deeper cost of not. For senior executives, founders, and operators who have ever sat in a boardroom and known something the room did not yet know - and wondered when, or whether, to say it out loud.The compliance architecture framework Nadia builds in this novel is not fiction. The author built it. OBSOLETE is a business literary novel This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

PAP. Zustand: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Zustand: New.

Paperback / softback. Zustand: New. New copy - Usually dispatched within 4 working days.

Zustand: As New. Unread book in perfect condition.

Zustand: New. 1st edition NO-PA16APR2015-KAP.

Zustand: New.

Zustand: New.

PAP. Zustand: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Paperback. Zustand: Brand New. 466 pages. 9.21x6.14x0.94 inches. In Stock.

Hardcover. Zustand: New. Brand new book, sourced directly from publisher. Dispatch time is 7-8 days from our warehouse. Book will be sent in robust, secure packaging to ensure it reaches you securely.

Zustand: New.

Zustand: New.

Zustand: As New. Unread book in perfect condition.

Hardcover. Zustand: new. Hardcover. Cancer clinical trials have become increasingly complex, requiring statistical methodologies that are both rigorous and flexible across diverse study designs. This book provides a comprehensive and practice-oriented overview of the statistical methods underpinning modern oncology drug development, covering the full continuum from early-phase studies through confirmatory trials and regulatory submission.Organized by development phase, the text presents principled approaches to dose-escalation and dose-optimization, proof-of-concept decision-making, and master protocol designs. It further details methodologies for late-stage trials, including sample size determination, group-sequential monitoring, time-to-event analysis, multiplicity adjustment, and adaptive designs, with particular attention to challenges such as delayed treatment effects.In addition to confirmatory trial methodology, the book addresses advanced analytical topics, including subgroup evaluation, treatment switching, multi-phase treatment strategies, and bias adjustment techniques. Contemporary issues in oncology researchsuch as the estimand framework, real-world evidence, seamless and platform trials, and emerging applications of artificial intelligence and machine learningare also discussed.Accessible yet rigorous, this book is an essential resource for biostatisticians, clinical researchers, and graduate students who want to design smarter trials, make better decisions, and accelerate the development of life-saving cancer therapies. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Zustand: As New. Unread book in perfect condition.

Hardcover. Zustand: new. Hardcover. Cancer clinical trials have become increasingly complex, requiring statistical methodologies that are both rigorous and flexible across diverse study designs. This book provides a comprehensive and practice-oriented overview of the statistical methods underpinning modern oncology drug development, covering the full continuum from early-phase studies through confirmatory trials and regulatory submission.Organized by development phase, the text presents principled approaches to dose-escalation and dose-optimization, proof-of-concept decision-making, and master protocol designs. It further details methodologies for late-stage trials, including sample size determination, group-sequential monitoring, time-to-event analysis, multiplicity adjustment, and adaptive designs, with particular attention to challenges such as delayed treatment effects.In addition to confirmatory trial methodology, the book addresses advanced analytical topics, including subgroup evaluation, treatment switching, multi-phase treatment strategies, and bias adjustment techniques. Contemporary issues in oncology researchsuch as the estimand framework, real-world evidence, seamless and platform trials, and emerging applications of artificial intelligence and machine learningare also discussed.Accessible yet rigorous, this book is an essential resource for biostatisticians, clinical researchers, and graduate students who want to design smarter trials, make better decisions, and accelerate the development of life-saving cancer therapies. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…

Zustand: New. pp. 468.

Zustand: New.

Zustand: New. pp. 468.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Cancer clinical trials have become increasingly complex, requiring statistical methodologies that are both rigorous and flexible across diverse study designs. This book provides a comprehensive and practice-oriented overview of the statistical methods underpinning modern oncology drug development, covering the full continuum from early-phase studies through confirmatory trials and regulatory submission.Organized by development phase, the text presents principled approaches to dose-escalation and dose-optimization, proof-of-concept decision-making, and master protocol designs. It further details methodologies for late-stage trials, including sample size determination, group-sequential monitoring, time-to-event analysis, multiplicity adjustment, and adaptive designs, with particular attention to challenges such as delayed treatment effects.In addition to confirmatory trial methodology, the book addresses advanced analytical topics, including subgroup evaluation, treatment switching, multi-phase treatment strategies, and bias adjustment techniques. Contemporary issues in oncology research such as the estimand framework, real-world evidence, seamless and platform trials, and emerging applications of artificial intelligence and machine learning are also discussed.Accessible yet rigorous, this book is an essential resource for biostatisticians, clinical researchers, and graduate students who want to design smarter trials, make better decisions, and accelerate the development of life-saving cancer therapies.…

Hardback. Zustand: New. New copy - Usually dispatched within 4 working days.